Key Highlights
- The stock fell to USD 0.0986 on Volume of 5.52M shares, a day after the Chapter 11 filing.
- Debtor-in-possession financing totals up to USD 110 million, including up to USD 55 million of new money.
- The plan projects a 0% recovery for common stock and Series A convertible preferred stock.
- Accelerated funded Debt includes USD 108.0 million of 2029 Notes and USD 113.5 million under a Revenue interest agreement.
- Fiscal 2025 revenue was USD 146.1 million with a net loss of USD 196.0 million.
What Moved the Stock Today (down USD 0.0134, 11.96%)
Karyopharm Therapeutics (NASDAQ:KPTI) was down 11.96% to USD 0.0986 in regular trading on November 3, 2026, on volume of 5.52M shares. That implies a Monday November 2, 2026 close of about USD 0.1120 (calculated). The screen shows a Market Capitalisation of about USD 2.24 million.
The decline came after the company disclosed on the evening of November 2, 2026 that it and its Subsidiary KPT Texas LLC had filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division.
The Chapter 11 Plan in Detail
According to an 8-K, the company signed a restructuring support agreement with lenders and noteholders holding 100% of its funded debt, certain Royalty investors, certain preferred holders and Ayrmid Ltd. The joint prepackaged plan would cancel existing common stock and Series A convertible preferred stock with no distribution. Projected recoveries are 78.9% for second-lien 2029 Notes claims and 16.5% for revenue interest financing claims.
Ayrmid is the stalking horse bidder, subject to higher or better offers. Under its term sheet, funded-debt claimholders and DIP lenders would receive 55% of the new company's common stock and Ayrmid's stockholders 45%, subject to adjustments, with a senior secured term Loan of up to USD 135 million. Closing is expected in the first quarter of 2027. Votes are due on November 30, 2026.
The company said it received five non-binding indications of interest before filing.
Business Background and Recent Results
Karyopharm is a commercial-stage oncology company that markets XPOVIO, an oral therapy for certain blood cancers, and is developing selinexor in myelofibrosis.
For fiscal 2025 it reported revenue of USD 146.1 million, a net loss of USD 196.0 million and Operating Cash Flow of negative USD 75.4 million. Second-quarter 2026 results were released on August 13, 2026. The filing notes that the FDA did not issue a refuse-to-file notice for the selinexor and ruxolitinib myelofibrosis application by its October 27, 2026 review deadline, with a filing communication expected around November 10, 2026.
Balance Sheet and Risks
The filing lists accelerated debt of about USD 129.0 million under the Credit agreement, USD 15.6 million of 2028 Notes, USD 108.0 million of 2029 Notes and USD 113.5 million under the revenue interest financing agreement. A forbearance period that had been extended to November 1, 2026 ended with the filing.
The debtor-in-possession Facility is a superpriority term loan of up to USD 110 million, split between up to USD 55 million of new money, with up to USD 25 million available on the interim order, and USD 55 million of roll-up loans. The filing also refers to an expected delisting from the Nasdaq Global Select Market, with no date given. As a penny stock, KPTI faces extreme volatility, thin Liquidity and a plan that expects no value for existing equity.
What to Watch Next
Near-term markers include the court's interim and final DIP orders, the bidding procedures and any competing offers, and a formal Nasdaq delisting notice. The plan milestones call for a final DIP order within 35 days of filing, an auction if needed within 60 days, and confirmation within 80 days.






Please wait processing your request...